Table 2.
Multivariable analyses of time of conversion from confirmed single GAD65 or non-GAD65 autoantibody (i.e., either mIAA or IA-2 autoantibody) positivity to multiple autoantibody positivity
| Time from confirmed single GAD65 autoantibody to multiple autoantibody positivity | ||||
|---|---|---|---|---|
| Factor |
HR (95% CI) |
P value |
||
| TCF7L2 rs4506565_T variant (1 or 2 minor alleles vs. 0) | 0.65 (0.44–0.97) | 0.033 | ||
| Age at single GAD65 autoantibody positivity | 0.99 (0.98–1.006) | 0.26 | ||
| HLA DR3-DQ2 and/or DR4-DQ8 |
1.66 (1.02–2.7) |
0.04 |
||
| Time from either mIAA or IA-2 autoantibody to multiple autoantibody positivity stratified by whether or not participants were overweight/obese* | ||||
| Factor |
Not overweight/obese (n = 51, 25 events) | Overweight/obese (n = 33, 22 events) | ||
| HR (95% CI) |
P value |
HR (95% CI) |
P value |
|
| TCF7L2 rs4506565_T variant (1 or 2 minor alleles vs. 0) | 0.80 (0.36–1.79) | 0.59 | 3.02 (1.23–7.45) | 0.016 |
| Age at single mIAA or IA-2 autoantibody positivity | 0.97 (0.93–1.01) | 0.14 | 0.97 (0.94–0.99) | 0.008 |
*HLA was removed from the model for being statistically nonsignificant.